How do TP53 mutations impact survival in patients with MPN?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak with Benjamin Rolles, Brigham and Women’s Hospital, Boston, US. We asked, How do TP53 mutations impact survival in patients with myeloproliferative neoplasms?

Firstly, Rolles summarizes key data presented during ASH and highlights the effects of single and multi-hit mutations on clinical outcomes. Then, he discusses the causes of higher mortality observed in patients with TP53 mutations and the difference in clinical performance between patients with single-hit and multi-hit mutations. Rolles concludes by discussing the potential of revising the risk stratification of patients with TP53 mutations to aid future clinical decisions.